Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UPA-750 is a near-infrared (NIR) fluorescent imaging probe designed for the detection of pancreatic adenocarcinoma. It consists of a urokinase plasminogen activator (uPA) peptide conjugated to the HiLyte-750 NIR dye. The probe specifically targets the urokinase plasminogen activator receptor (uPAR), which is highly expressed in various pancreatic cancer cell lines. UPA-750 is utilized in conjunction with multispectral optoacoustic tomography (MSOT) to identify hypovascularized pancreatic tumors, which are often difficult to detect using conventional contrast agents. Preclinical studies in orthotopic pancreatic cancer xenografts have demonstrated that the probe selectively accumulates in tumor tissue, allowing for enhanced visualization and biodistribution monitoring.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UPA-750.